OKYO Pharma Ltd's Gary Jacob tells Proactive it's been issued a new patent containing key claims covering its drug OK-101 to treat neuropathic pain. OK-101 is the company's lead pre-clinical compound - a novel long-acting anti-inflammatory drug candidate being developed to treat patients with dry eye disease.
OKYO Pharma granted new patent for OK-101 to treat neuropathic pain
